HRSA Tells 50-Plus Drug Makers To Refund 340B Hospitals Overcharged For Orphan Drugs

The Health Resources and Services Administration has told more than 50 drug manufacturers to refund 340B hospitals for certain orphan drugs charged at non-discounted prices, complaining the companies did not follow the agency's controversial orphan drug policy that has been the subject of two drug industry court challenges. HRSA told Inside Health Policy a letter was sent on Oct. 7 giving the manufacturers 30 days to “notify HRSA of plans to repay affected covered entities and to institute the...